Nevertheless, IDH-mutation as a significant early mutation site of glioma has also been proposed to no longer regulates tumor proliferation and invasion after tumor formation [349], So, the prospect of IDH-mutation as a therapeutic target in LGG remains controversial. This evidence concerns the gene IDH1 and glioma.